menu search

Revolution medicines to present new clinical data at major oncology conferences and host investor webcast

Interim Data to be Presented for RMC-6236 (RASMULTI(ON) Inhibitor) and RMC-6291 (RASG12C(ON) Inhibitor) Company to Host Investor Webcast Following ESM...

October 4, 2023, 8:05 pm

Immuneering to present preclinical data on imm-1-104 and imm-6-415 at aacr-nci-eortc international conference on molecular targets and cancer therapeutics

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for...

October 4, 2023, 4:05 pm

Omega therapeutics to present new preclinical data on otx-2101 at the 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pion...

October 4, 2023, 4:00 pm

Kura oncology announces three presentations at aacr-nci-eortc international conference on molecular targets and cancer therapeutics

– Presentations to highlight preclinical data supporting combination of KO-2806 with targeted therapies, including TKIs, KRASG12C inhibitors and KRA...

October 4, 2023, 11:30 am

Foghorn therapeutics to present clinical and pre-clinical data from multiple programs across its diverse pipeline at aacr-nci-eortc international conference

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a ne...

October 4, 2023, 8:00 am

Karuna therapeutics to present data from the emergent program evaluating karxt in schizophrenia at the 36th european college of neuropsychopharmacology (ecnp) congress

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative...

October 4, 2023, 6:30 am

Biotechnology breakthroughs: 3 biotech stocks that could make early investors rich

In the landscape of modern medicine, a trio of biotech giants may rewrite the rules of healthcare. In a world where precision and personalization have...

October 3, 2023, 5:00 pm

Novartis ceo: company set to become a pure play, innovative medicine business after sandoz spin off

Vas Narasimhan, CEO at Novartis, discusses the company's 100% spin off of Sandoz, its generic and biosimilar medicines business, and what the deal mea...

October 3, 2023, 11:26 am

Editas medicine: ruby gems, sparkling catalysts in sickle cell arena

Editas Medicine's reduced R&D costs and strong cash position provide operational comfort but necessitate future capital, especially amid looming compe...

October 3, 2023, 2:59 am

Astrazeneca to pay $425 mln to settle nexium, prilosec litigation in us

British drugmaker AstraZeneca on Tuesday said it will pay $425 million to settle product liability litigations related to acid-reflux ...

October 3, 2023, 2:16 am

Drugmakers sign on to negotiate medicare prices under protest

All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S. Medicare health program, includin...

October 2, 2023, 1:02 pm

Clade therapeutics announces the acquisition of gadeta b.v.

Expands Clade’s pipeline and broadens its platform with:– proprietary gamma/delta (g/d) TCR universal targeting platform technology,– g/d TCR ca...

October 2, 2023, 12:30 pm

Moonshot medicine: 3 stocks to buy to bet on long-shot drugs

Clinical trials are a difficult and grueling process for companies. The FDA and other regulatory agencies require the highest possible standards in or...

September 30, 2023, 3:00 pm

Why editas medicine stock is soaring today

Stifel upgraded Editas medicine stock from hold to buy and raised the price target from $9 to $17. The ...

September 29, 2023, 11:21 am

Why is opgen (opgn) stock up 115% today?

OpGen (NASDAQ: OPGN ) stock is on the rise Friday after the precision medicine company withdrew a shar...

September 29, 2023, 8:22 am

Organogenesis applauds withdrawal of local coverage determinations by novitas, first coast service options and cgs

Thanks Stakeholders who Advocated for Patients CANTON, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leadin...

September 28, 2023, 1:15 pm

Nektar (nktr), cellular biomedicine join for lung cancer studies

Nektar (NKTR) enters into a deal with Cellular Biomedicine Group to develop NKTR-255 in combination wit...

September 28, 2023, 9:01 am

Aclaris therapeutics: the many lives of this biopharmaceutical developer

Aclaris Therapeutics is a developer of kinome-based medicines for immune-inflammatory and oncology indications. The company's platform, KINect, helps ...

September 28, 2023, 7:18 am

Crispr therapeutics to present at the society for immunotherapy of cancer (sitc) 38th annual meeting

ZUG, Switzerland and BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating tr...

September 27, 2023, 9:01 am

Prime medicine: not yet primed for retail investment

Prime medicine is developing prime editing, a highly precise gene editing technology that offers advant...

September 27, 2023, 8:49 am


Search within

Pages Search Results: